These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30650219)

  • 1. Pharmacology of bisphosphonates.
    Cremers S; Drake MT; Ebetino FH; Bilezikian JP; Russell RGG
    Br J Clin Pharmacol; 2019 Jun; 85(6):1052-1062. PubMed ID: 30650219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment.
    Allen MR
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1371-8. PubMed ID: 18950279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant.
    Machairiotis N; Ntali G; Kouroutou P; Michala L
    Horm Mol Biol Clin Investig; 2019 Sep; 40(2):. PubMed ID: 31539355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: how do they work?
    Papapoulos SE
    Best Pract Res Clin Endocrinol Metab; 2008 Oct; 22(5):831-47. PubMed ID: 19028359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the treatment of metabolic bone diseases.
    Arantes HP; Silva AG; Lazaretti-Castro M
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):206-12. PubMed ID: 20485910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in the treatment of metabolic bone diseases.
    Rodan GA; Balena R
    Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacometrics and systems pharmacology for metabolic bone diseases.
    Riggs MM; Cremers S
    Br J Clin Pharmacol; 2019 Jun; 85(6):1136-1146. PubMed ID: 30690761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do bisphosphonates affect fracture healing?
    Kates SL; Ackert-Bicknell CL
    Injury; 2016 Jan; 47 Suppl 1(0 1):S65-8. PubMed ID: 26768295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.
    Dionísio MR; Mansinho A; Abreu C; Cavaco-Silva J; Casimiro S; Costa L
    Br J Clin Pharmacol; 2019 Jun; 85(6):1114-1124. PubMed ID: 30601585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and osteonecrosis: potential treatment or serious complication?
    Goytia RN; Salama A; Khanuja HS
    Orthop Clin North Am; 2009 Apr; 40(2):223-34. PubMed ID: 19358907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?
    Verron E; Bouler JM
    Drug Discov Today; 2014 Mar; 19(3):312-9. PubMed ID: 23974069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development.
    Soares AP; do Espírito Santo RF; Line SR; Pinto Md; Santos Pde M; Toralles MB; do Espírito Santo AR
    Environ Toxicol Pharmacol; 2016 Mar; 42():212-7. PubMed ID: 26895384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the pharmacological evaluation of bisphosphonates in humans.
    Cremers S; Ebetino FH; Phipps R
    Bone; 2020 Oct; 139():115501. PubMed ID: 32599224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
    Uebelhart B; Rizzoli R; Ferrari SL
    Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.